Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

NCT01148407CI-TRIAL-00004717unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Cancer	Malignant Neoplasm	ALIAS	0.90

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Patients with a diagnosis of malignancy

Exclusion Criteria:

* Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Jun 1, 2010
Primary completion: Aug 1, 2012
Completion: Aug 1, 2013
First posted: Jun 22, 2010
Last update posted: Apr 22, 2011
Enrollment: 30 (estimated)
Lead sponsor: University of Vermont OTHER
Keywords: breast cancer, platelets, metastatic cancer, malignancy

Data updated 22 days agoSource updated Apr 22, 2011source: clinicaltrials

Locations

Locations by country (1)

Country	Sites	Recruiting
United States	1	1

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.